Department of Otorhinolaryngology-Head and Neck Surgery, Otorhinolaryngology Research Center, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
USC Caruso Department of Otolaryngology-Head and Neck Surgery, Los Angeles, California, USA.
Otolaryngol Head Neck Surg. 2024 Jul;171(1):35-44. doi: 10.1002/ohn.717. Epub 2024 Mar 15.
Provide clinicians with current evidence for biologic therapy in children with chronic rhinosinusitis with nasal polyposis (CRSwNP).
PubMed, MEDLINE, Cochrane, and clinical trial registries.
Key search terms related to biologic therapy in pediatric CRSwNP were identified via a structured query of current medical literature and clinical trial databases.
There is a dearth of active clinical trials and research studies for biologics targeting pediatric CRSwNP. There is an ongoing compassionate-use clinical trial involving Dupilumab for children with nasal polyps as well as only 1 published work specifically focused on Dupilumab for pediatric CRSwNP in the setting of aspirin-exacerbated respiratory disease.
For children with atopic dermatitis, asthma, and chronic idiopathic urticaria, biologic therapies such as Omalizumab, Dupilumab, and Mepolizumab have gained Food and Drug Administration approval. The role of biologic therapy in pediatric CRSwNP demonstrates significant promise in the comprehensive management of the unified airway. Additional Phase III trials are necessary to broaden clinical indications for children with comorbid conditions and complex sinonasal disease.
为临床医生提供慢性鼻-鼻窦炎伴鼻息肉（CRSwNP）儿童生物治疗的最新证据。
PubMed、MEDLINE、Cochrane 和临床试验注册处。
通过对当前医学文献和临床试验数据库的结构化查询，确定与儿科 CRSwNP 生物治疗相关的关键搜索词。
针对儿科 CRSwNP 的生物制剂的临床试验和研究很少。目前正在进行一项涉及 Dupilumab 的同情使用临床试验，用于治疗鼻息肉患儿，并且仅在阿司匹林加重性呼吸道疾病背景下，有 1 项专门针对 Dupilumab 治疗儿科 CRSwNP 的已发表研究。
对于特应性皮炎、哮喘和慢性特发性荨麻疹患儿，奥马珠单抗、Dupilumab 和 Mepolizumab 等生物疗法已获得美国食品和药物管理局的批准。生物疗法在儿科 CRSwNP 中的作用在联合气道的综合管理中显示出巨大的潜力。需要进行更多的 III 期临床试验，以扩大对合并症和复杂鼻-鼻窦疾病患儿的临床适应证。
